KO Client Cloudbreak Pharma Enters into Licensing Agreement with Santen

KO client Cloudbreak Pharma, an innovative clinical-stage ophthalmology biotechnology company, recently announced that it has entered into a licensing agreement with Santen, a specialized company dedicated to eye health, to develop, manufacture, and commercialize its topical pterygium treatment.

Cloudbreak founder and CEO Jinsong Ni said: “We are excited to partner with Santen, a company renowned for its commitment to quality, innovation and patient eye health. “Our shared vision and combined expertise mark a significant step forward in our mission to bring this promising disease-modifying therapy to market swiftly to patients with pterygium in Japan and around the world.”

The KO team, led by partner Brad Schoenfeld, represented Cloudbreak in this agreement.

“KO Law was invaluable to successfully closing Cloudbreak’s licensing agreement with Santen,” said Ni. “Brad provided top-tier legal experience and significant industry expertise that was critical to heavily negotiating and successfully closing this complex, cross-border transaction that will help bring our disease-modifying therapy to market swiftly.”

To learn more, check out Cloudbreak’s announcement.